Ensure Long-Acting Beta-Agonists Aren't Used Alone for Asthma

February 2018

Labeling changes will bring up questions about the role of long-acting beta-agonists (LABAs) for asthma.

We've heard about early studies that suggest using a LABA withOUT an inhaled corticosteroid (ICS) increases the risk of asthma death.

This led to FDA's boxed warning in 2003 to stop LABAs once asthma is controlled...and required manufacturers to study the safety of LABAs in combo with inhaled steroids.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote